论文部分内容阅读
目的分析曲美他嗪对房颤伴冠心病患者心力衰竭的影响。方法取某院心内科于2008年4月～2011年4月间收治的房颤伴冠心病患者84例作为研究对象,均经临床确诊,随机分为观察组与对照组各42例。对照组患者使用心内科冠心病心力衰竭常规治疗,观察组患者在常规治疗的基础上,加用曲美他嗪治疗,比较两组患者的临床疗效及心功能指标差异。结果观察组患者的治疗效果明显优于对照组,两者差异有统计学意义(P﹤0.05);观察组患者治疗后心功能指标明显优于对照组(P﹤0.05)。结论曲美他嗪可以有效改善房颤伴冠心病患者的临床疗效,缓解其心力衰竭状况,改善各项心功能指标,具有积极的临床意义。
Objective To analyze the effect of trimetazidine on heart failure in patients with atrial fibrillation and coronary heart disease. Methods Totally 84 patients with atrial fibrillation and coronary heart disease admitted from April 2008 to April 2011 in our hospital from April 2008 to April 2011 were randomly divided into observation group (42 cases) and control group (42 cases). Patients in the control group were treated with cardiopulmonary eradication and conventional treatment of heart failure. Patients in the observation group were treated with trimetazidine based on routine treatment. The clinical efficacy and cardiac function were compared between the two groups. Results The therapeutic effect of the observation group was better than that of the control group, the difference was statistically significant (P <0.05). The cardiac function of the observation group was significantly better than that of the control group after treatment (P <0.05). Conclusion Trimetazidine can effectively improve the clinical efficacy of patients with atrial fibrillation and coronary heart disease, relieve their heart failure status and improve cardiac function, which has a positive clinical significance.